Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

Table ST6 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma

<p>Table ST6: Differential expressed lipids and their FDRs in sensitive vs resistant cells (negative values are upregulated in sensitive cells).</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Ossia M. Eichhoff (14964145) (author)
Rannpháirtithe:	Corinne I. Stoffel (14964148) (author), Jan Käsler (14964151) (author), Luzia Briker (14964154) (author), Patrick Turko (14964157) (author), Gergely Karsai (14964160) (author), Nina Zila (14964163) (author), Verena Paulitschke (14964166) (author), Phil F. Cheng (14940278) (author), Alexander Leitner (14964169) (author), Andrea Bileck (14964172) (author), Nicola Zamboni (14964175) (author), Anja Irmisch (14964178) (author), Zsolt Balazs (14964181) (author), Aizhan Tastanova (14964184) (author), Susana Pascoal (14964187) (author), Pål Johansen (14964190) (author), Rebekka Wegmann (6698010) (author), Julien Mena (14964193) (author), Alaa Othman (14964196) (author), Vasanthi S. Viswanathan (14964199) (author), Judith Wenzina (14964202) (author), Andrea Aloia (14964205) (author), Annalisa Saltari (14964208) (author), Andreas Dzung (14964211) (author), Michael Krauthammer (14964214) (author), Stuart L. Schreiber (14964217) (author), Thorsten Hornemann (14964220) (author), Martin Distel (14964223) (author), Berend Snijder (14964226) (author), Reinhard Dummer (14850772) (author), Mitchell P. Levesque (14964229) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Drug Resistance Reversal of drug resistance Metabolism Metabolomics Skin Cancers Melanoma Tumor Heterogeneity
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Table ST1 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST2 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST3 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST4 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST5 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST7 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST8 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Table ST9 from ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma
de réir: Ossia M. Eichhoff (14964145)
Foilsithe / Cruthaithe: (2025)

Figure S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Table S1 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Table S3 from Ccr2<sup>+</sup> Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in <i>Braf</i>-Mutant Melanoma
de réir: Dahihm Kim (16546203)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
de réir: Phyllis S.Y. Chong (17141520)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Histone Methyltransferase NSD2 Activates PKCα to Drive Metabolic Reprogramming and Lenalidomide Resistance in Multiple Myeloma
de réir: Phyllis S.Y. Chong (17141520)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
de réir: Nicole A. Traphagen (16677391)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer
de réir: Nicole A. Traphagen (16677391)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S5 from <i>RBM10</i> Loss Promotes <i>EGFR</i>-Driven Lung Cancer and Confers Sensitivity to Spliceosome Inhibition
de réir: Yufang Bao (15386826)
Foilsithe / Cruthaithe: (2025)

Data file S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S2 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S3 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S4 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Data file S5 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Table S1 from Targeting STAT5 Signaling Overcomes Resistance to IDH Inhibitors in Acute Myeloid Leukemia through Suppression of Stemness
de réir: Alex C.H. Liu (14961921)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
de réir: Kavya Ramkumar (16474203)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S1 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S3 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S4 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S5 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S6 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S7 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Figure S8 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Supplementary Table 2 from Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma
de réir: Andrew W. Hahn (15024693)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_fslqq9ubml1gi1nirfu0ldce0c